Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases

查看全文 作　　者：Heinrich [1]Steinhoff;Miklos [1]Acs;Sebastian [1]Blaj;Magdolna [2]Dank;Magdolna [3]Herold;Zoltan [2]Herold;Jonas [4]Herzberg;Patricia Sanchez-[5]Velazquez;Tim [4]Strate;Attila Marcell [2]Szasz;Pompiliu [1]Piso

机构地区：[1]Department of General and Visceral Surgery,Hospital Barmherzige Brüder,Regensburg 93049,Germany;[2]Division of Oncology,Department of Internal Medicine and Oncology,Semmelweis University,Budapest 1083,Hungary;[3]Department of Internal Medicine and Hematology,Semmelweis University,Budapest 1088,Hungary;[4]Department of Surgery,Krankenhaus Reinbek St.Adolf-Stift,Reinbek 21465,Germany;[5]Department of General Surgery,Hospital del Mar,Barcelona 08003,Spain

出　　处：《World Journal of Gastroenterology》索引2023年第29卷第18期,共14页

摘　　要：BACKGROUND Advanced gastric cancer with synchronous peritoneal metastases(GC-PM)is associated with a poor prognosis.Although cytoreductive surgery with hyperthermic intraperitoneal chemotherapy(CRS-HIPEC)is a promising approach,only a limited number of Western studies exist.AIM To investigate the clinicopathological outcomes of patients who underwent CRSHIPEC for GC-PM.METHODS A retrospective analysis of patients with GC-PM was conducted.All patients were seen at the Department of General and Visceral Surgery,Hospital Barmherzige Brüder,Regensburg,Germany between January 2011 and July 2021 and underwent CRS-HIPEC.Preoperative laboratory results,the use of neoadjuvant trastuzumab,and the details of CRS-HIPEC,including peritoneal carcinomatosis index,completeness of cytoreduction,and surgical procedures were recorded.Disease-specific(DSS),and overall survival(OS)of patients were calculated.RESULTS A total of 73 patients were included in the study.Patients treated with neoadjuvant trastuzumab(n=5)showed longer DSS(P=0.0482).Higher white blood cell counts(DSS:P=0.0433)and carcinoembryonic antigen levels(OS and DSS:P<0.01),and lower hemoglobin(OS and DSS:P<0.05)and serum total protein(OS:P=0.0368)levels were associated with shorter survival.Longer HIPEC duration was associated with more advantageous median survival times[60-min(n=59):12.86 mo;90-min(n=14):27.30 mo],but without statistical difference.To obtain additional data from this observation,further separation of the study population was performed.First,propensity score-matched patient pairs(n=14 in each group)were created.Statistically different DSS was found between patient pairs(hazard ratio=0.2843;95%confidence interval:0.1119-0.7222;P=0.0082).Second,those patients who were treated with trastuzumab and/or had human epidermal growth factor receptor 2 positivity(median survival:12.68 mo vs 24.02 mo),or had to undergo the procedure before 2016(median survival:12.68 mo vs 27.30 mo;P=0.0493)were removed from the original study population.CONCLUSION Based on our experience,CRS-HIPEC is a safe and secure method to improve the survival of advanced GC-PM patients.Prolonged HIPEC duration may serve as a good therapy for these patients. 关键词：Cytoreductive surgery Hyperthermic intraperitoneal chemotherapy Peritoneal metastasis Stomach neoplasms Gastric cancer

相关文献

参考文献（58）
引证文献（3）
耦合文献（0）

参考文献(58)

引证文献(3)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases

参考文献(58)

引证文献(3)

用户提示